Since 2020, based on evidence from well-designed studies such as KRISTINE, TRAIN-2, and TRYPHENA, both NCCN and CSCO guidelines have prioritized the TCbHP regimen as a preferred option in NAT for HER2-positive BC patients (7–9). The gene discussed is BRD2; the disease is breast cancer.